vs
艾伯维（ARGX）与BioNTech SE（BNTX）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是BioNTech SE的1.6倍（$2.5B vs $1.5B）。艾伯维净利率更高（35.5% vs -1.9%，领先37.4%）
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
BioNTech SE是总部位于德国美因茨的跨国生物技术企业，专注于免疫疗法及疫苗研发工作，核心研究方向覆盖肿瘤、传染性疾病等医疗领域，相关技术处于全球生物医药行业领先水平。
ARGX vs BNTX — 直观对比
营收规模更大
ARGX
是对方的1.6倍
$1.5B
净利率更高
ARGX
高出37.4%
-1.9%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $1.5B |
| 净利润 | $877.2M | $-28.7M |
| 毛利率 | 89.5% | — |
| 营业利润率 | 28.9% | -3.1% |
| 净利率 | 35.5% | -1.9% |
| 营收同比 | 83.2% | — |
| 净利润同比 | 1.3% | — |
| 每股收益（稀释后） | $13.25 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARGXBNTX
| Q4 25 | $2.5B | — | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $1.8B | $260.8M | ||
| Q1 25 | — | $182.8M | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | $901.9M | $128.7M | ||
| Q1 24 | — | $187.6M |
净利润ARGXBNTX
| Q4 25 | $877.2M | — | ||
| Q3 25 | — | $-28.7M | ||
| Q2 25 | $414.8M | $-386.6M | ||
| Q1 25 | — | $-415.8M | ||
| Q4 24 | $865.6M | — | ||
| Q3 24 | — | $198.1M | ||
| Q2 24 | $-32.5M | — | ||
| Q1 24 | — | — |
毛利率ARGXBNTX
| Q4 25 | 89.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 90.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 89.4% | — | ||
| Q1 24 | — | — |
营业利润率ARGXBNTX
| Q4 25 | 28.9% | — | ||
| Q3 25 | — | -3.1% | ||
| Q2 25 | 19.2% | -192.1% | ||
| Q1 25 | — | -292.2% | ||
| Q4 24 | 8.7% | — | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | -15.4% | -750.7% | ||
| Q1 24 | — | -270.4% |
净利率ARGXBNTX
| Q4 25 | 35.5% | — | ||
| Q3 25 | — | -1.9% | ||
| Q2 25 | 23.4% | -148.2% | ||
| Q1 25 | — | -227.5% | ||
| Q4 24 | 64.1% | — | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | -3.6% | — | ||
| Q1 24 | — | — |
每股收益（稀释后）ARGXBNTX
| Q4 25 | $13.25 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $6.32 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $13.33 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.55 | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5B | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3B | — |
| 总资产 | $8.7B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARGXBNTX
| Q4 25 | $3.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | — | — |
总债务ARGXBNTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $11.0M | — | ||
| Q1 24 | — | — |
股东权益ARGXBNTX
| Q4 25 | $7.3B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $6.1B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $5.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $4.3B | — | ||
| Q1 24 | — | — |
总资产ARGXBNTX
| Q4 25 | $8.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.2B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $6.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $4.8B | — | ||
| Q1 24 | — | — |
负债/权益比ARGXBNTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $323.3M | — |
| 自由现金流经营现金流 - 资本支出 | $322.4M | — |
| 自由现金流率自由现金流/营收 | 13.0% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.37× | — |
| 过去12个月自由现金流最近4个季度 | $594.5M | — |
8季度趋势，按日历期对齐
经营现金流ARGXBNTX
| Q4 25 | $323.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $361.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $41.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-124.7M | — | ||
| Q1 24 | — | — |
自由现金流ARGXBNTX
| Q4 25 | $322.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $356.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $40.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-125.5M | — | ||
| Q1 24 | — | — |
自由现金流率ARGXBNTX
| Q4 25 | 13.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 20.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.9% | — | ||
| Q1 24 | — | — |
资本支出强度ARGXBNTX
| Q4 25 | 0.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | — | — |
现金转化率ARGXBNTX
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.87× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
